Department of Oncology (IV), Heilongjiang Provincial General Hospital of Agricultural Reclamation, Second Cancer Hospital of Heilongjiang Province, Harbin, P.R. China.
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6759-6766. doi: 10.26355/eurrev_202006_21664.
To investigate the expression and clinical significance of costimulatory molecule B7-H3 and microRNA-145 (miR-145) in lung cancer patients with malignant pleural effusion.
A total of 100 cases of patients with lung cancer who admitted to our hospital for treatment from March 2017 to September 2018 were selected. Forty-nine cases of patients diagnosed with malignant pleural effusion were included in the study group, and 51 cases with benign pleural effusion in the control group. The content of B7-H3 in pleural effusion of the two groups was detected by enzyme-linked immunosorbent assay (ELISA), and the expression of miR-145 in pleural effusion of the two groups was analyzed by Real-time quantitative PCR (qRT-PCR). The relationships between the expressions of B7-H3 and miR-145 and the clinicopathological characteristics were analyzed. The diagnostic value of B7-H3 and miR-145 in lung cancer was analyzed.
The expression level of B7-H3 in the study group was significantly higher than that in the control group (p<0.050), while the expression level of miR-145 was significantly lower than that in the control group (p<0.050). The expression levels of B7-H3 and miR-145 in the study group were correlated with lymph node metastasis, differentiation degree of lung cancer and TNM stage (p<0.001). The sensitivity and specificity of miR-145 in single diagnosis of lung cancer were 64.71% and 79.59%, respectively. The sensitivity and specificity of B7-H3 in single diagnosis of lung cancer were 80.39% and 61.22%, respectively.
B7-H3 and miR-145 are abnormally expressed in lung cancer, and are closely related to the lymphatic metastasis, differentiation degree and TNM stage of lung cancer. They may be potential markers for the diagnosis of malignant pleural effusion in lung cancer in the future.
研究共刺激分子 B7-H3 和 microRNA-145（miR-145）在肺癌合并恶性胸腔积液患者中的表达及临床意义。
选取 2017 年 3 月至 2018 年 9 月我院收治的肺癌患者 100 例，其中诊断为恶性胸腔积液的 49 例患者纳入研究组，良性胸腔积液的 51 例患者纳入对照组。采用酶联免疫吸附试验（ELISA）检测两组胸腔积液中 B7-H3 含量，实时荧光定量 PCR（qRT-PCR）分析两组胸腔积液中 miR-145 的表达，分析 B7-H3、miR-145 表达与临床病理特征的关系，分析 B7-H3、miR-145 对肺癌的诊断价值。
研究组 B7-H3 表达水平明显高于对照组（p<0.050），miR-145 表达水平明显低于对照组（p<0.050）。研究组 B7-H3、miR-145 表达水平与淋巴结转移、肺癌分化程度及 TNM 分期有关（p<0.001）。miR-145 单项诊断肺癌的灵敏度和特异度分别为 64.71%、79.59%，B7-H3 单项诊断肺癌的灵敏度和特异度分别为 80.39%、61.22%。
B7-H3、miR-145 在肺癌中异常表达，与肺癌的淋巴转移、分化程度及 TNM 分期密切相关，可能成为未来肺癌恶性胸腔积液诊断的潜在标志物。
